HidehoOkadaMD
Neurosurgery • San Francisco, CAAssociate Professor, Neurological Surgery, University of Pittsburgh School of Medicine
Dr. Okada is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1450 3rd Street
San Francisco, CA 94158Phone+1 415-476-1637
Education & Training
Nagoya University - School of MedicineClass of 1991
Certifications & Licensure
PA State Medical License 2004 - 2014
Awards, Honors, & Recognition
- Elected Member The American Society for Clinical Investigation, 2010
Clinical Trials
- H3.3K27M Peptide Vaccine With Nivolumab for Children With Newly Diagnosed DIPG and Other Gliomas Start of enrollment: 2016 Nov 18
Publications & Presentations
PubMed
- 1 citationsTumour-wide RNA splicing aberrations generate actionable public neoantigens.Darwin W Kwok, Nicholas O Stevers, Iñaki Etxeberria, Takahide Nejo, Maggie Colton Cove
Nature. 2025-03-01 - 1 citationsChimeric antigen receptor T-cell therapy in patients with malignant glioma-From neuroimmunology to clinical trial design considerations.Marco Gallus, Jacob S Young, Sarah Cook Quackenbush, Mustafa Khasraw, John de Groot
Neuro-Oncology. 2025-02-10 - 2 citationsCurrent and Future Roles of Chimeric Antigen Receptor T-Cell Therapy in Neurology: A Review.Fatme Seval Ismail, Marco Gallus, Sven G Meuth, Hideho Okada, Hans-Peter Hartung
JAMA Neurology. 2025-01-01
Journal Articles
- Immunotherapy of Primary Brain Tumors: Facts and HopesHideho Okada, MD, Clinical Cancer Research
- Single-Cell Profiling of Human Gliomas Reveals Macrophage Ontogeny as a Basis for Regional Differences in Macrophage Activation in the Tumor MicroenvironmentDaniel A Lim, S John Liu, Manish Aghi, Hideho Okada, Nduka M Amankulor, Arnold R Kriegstein, BioMed Central
Press Mentions
Jumbled Proteins Paint a Bold Target on the Backs of Brain TumorsFebruary 19th, 2025- Killer T Cells Programmed for Tissue- and Tumor-Specific TargetingDecember 6th, 2024
- Molecular Zip Code Draws Killer T Cells to Brain TumorsDecember 5th, 2024
- Join now to see all
Grant Support
- Preclinical development of breakthrough immunotherapy for brain tumorsUNIVERSITY OF CALIFORNIA, SAN FRANCISCO2017–2025
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
